TechFlow reported on March 6 that, according to Globe Newswire, the board of biotech company BioNexus Gene Lab Corp has approved a strategic Ethereum treasury allocation and released a related strategy whitepaper, allocating part of its funds to the Ethereum ecosystem.
The company stated this strategy aims to optimize financial management while exploring the potential applications of blockchain technology in the biotechnology field. The strategy whitepaper details how the company plans to leverage Ethereum's smart contract capabilities and decentralized features to create new opportunities for business development.
Add to Favorites
Share to Social Media
